These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 8797878)

  • 41. [Tumor-associated antigens and fibrin derivatives as reaction products of ovarian cancer].
    Schröck R; Hafter R; Schmid L; Babic R; Ulm K; Gössner W; Graeff H
    Geburtshilfe Frauenheilkd; 1986 Jan; 46(1):1-10. PubMed ID: 2420679
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Preoperative value of CA 125 as a reflection of tumor grade in epithelial ovarian cancer.
    But I; Gorisek B
    Gynecol Oncol; 1996 Nov; 63(2):166-72. PubMed ID: 8910622
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CA 125 in ovarian cancer.
    van der Burg ME; Lammes FB; Verweij J
    Neth J Med; 1992 Feb; 40(1-2):36-51. PubMed ID: 1579185
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Significance of CA 125 serum level in discrimination between benign and malignant masses in the pelvis.
    Milojkovic M; Hrgovic Z; Hrgovic I; Jonat W; Maass N; Buković D
    Arch Gynecol Obstet; 2004 Mar; 269(3):176-80. PubMed ID: 14557888
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Clinical significance of new tumor marker CA 125 in gynecological cancer--particularly usefulness in diagnosis of ovarian cancer].
    Kimura E; Murae M; Koga R; Odawara Y; Nakabayashi Y; Yokoyama K; Nakata H; Totake T; Ochiai K; Yasuda M
    Nihon Sanka Fujinka Gakkai Zasshi; 1984 Nov; 36(11):2121-8. PubMed ID: 6595320
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ovarian tumors of low malignant potential (borderline tumors): immune morphology and current status.
    Neunteufel W; Gitsch G; Schieder K; Kölbl H; Breitenecker G
    Anticancer Res; 1989; 9(4):993-7. PubMed ID: 2684001
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CA 125 in ovarian cysts, serous effusions and peritoneal washings: immunocytochemical expression.
    Carico E; Chicchirichi R; Atlante M; Giovagnoli M; Vecchione A
    Anticancer Res; 1995; 15(2):631-4. PubMed ID: 7763049
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Significance of CA 125 antigen levels in patients with ovarian cancer].
    Shimizu Y; Fujiwara H; Akagaki E; Hirota K; Kono M; Irie T; Miura S; Okudaira Y
    Gan To Kagaku Ryoho; 1986 Jan; 13(1):46-52. PubMed ID: 3455806
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
    Koelbl H; Schieder K; Neunteufel W; Bieglmayer C
    Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tumor-associated antigen Ca 125 before and during the treatment of ovarian carcinoma.
    Kivinen S; Kuoppala T; Leppilampi M; Vuori J; Kauppila A
    Obstet Gynecol; 1986 Apr; 67(4):468-72. PubMed ID: 3008051
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The clinicopathological significance of Bax and Bcl-2 protein expression with tumor infiltrating lymphocytes in ovarian carcinoma.
    Yigit S; Demir L; Tarhan MO; Cabuk FK; Ellidokuz H; Erten C; Somali I; Dirican A; Cakalagaoglu F
    Neoplasma; 2012; 59(5):475-85. PubMed ID: 22668011
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [The value of CA 125 determination in the serum of patients with ovarian cancer].
    Bartel U; Johannsen B; Elling D
    Zentralbl Gynakol; 1989; 111(5):301-9. PubMed ID: 2728673
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tissue expression of CA 125 in benign and malignant lesions of ovary and fallopian tube: a comparison with CA 19-9 and CEA.
    Neunteufel W; Breitenecker G
    Gynecol Oncol; 1989 Mar; 32(3):297-302. PubMed ID: 2646183
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Simultaneous determination of Ca 125 and D-dimer in plasma and ascites in ovarian cancer].
    Schröck R; Hafter R; Graeff H; Schmid L
    Onkologie; 1985 Oct; 8(5):260-2. PubMed ID: 2999668
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Use of CA 125 monoclonal antibody to monitor patients with ovarian cancer.
    Kudlacek S; Schieder K; Kölbl H; Neunteufel W; Nowotny C; Breitenecker G; Biegelmayer G; Vetterlein M; Fürlinger B; Micksche M
    Gynecol Oncol; 1989 Dec; 35(3):323-9. PubMed ID: 2480931
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Differentiation between borderline and benign ovarian tumors: combined analysis of MRI with tumor markers for large cystic masses (≥5 cm).
    Park SY; Oh YT; Jung DC
    Acta Radiol; 2016 May; 57(5):633-9. PubMed ID: 26231948
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Monoclonal antibodies in the diagnosis and follow-up of ovarian cancer. CA 125 as a tumor marker. A cooperative study of the Gynecologic Tumor Marker Group (GTMG)].
    Kaesemann H; Caffier H; Hoffmann FJ; Crombach G; Würz H; Kreienberg R; Möbus V; Schmidt-Rhode P; Sturm G
    Klin Wochenschr; 1986 Sep; 64(17):781-5. PubMed ID: 3463828
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prospective study of serum CA-125 levels as markers of ovarian cancer.
    Helzlsouer KJ; Bush TL; Alberg AJ; Bass KM; Zacur H; Comstock GW
    JAMA; 1993 Mar; 269(9):1123-6. PubMed ID: 8433467
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Serum LDH and CA-125: Markers for Diagnosis of Ovarian Malignancy.
    Deeba F; Khatun S; Alam MM; Shahida SM
    Mymensingh Med J; 2015 Apr; 24(2):334-40. PubMed ID: 26007262
    [TBL] [Abstract][Full Text] [Related]  

  • 60. CA 125 as a tumour marker in epithelial ovarian cancer.
    Sheehan JD; Duffy MJ; Allen MA; Fennelly JJ
    Ir J Med Sci; 1989 Jan; 158(1):10-3. PubMed ID: 2737852
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.